FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006295669> ?p ?o ?g. }

• W3006295669 endingPage "102498" @default.
• W3006295669 startingPage "102498" @default.
• W3006295669 abstract "Myastenia-Inflammatory Myopathy (MG-IM) association has been described in less than 50 cases, as isolated reports or in few case series. In most cases, MG and IM onset occur simultaneously even if the overlapping clinical manifestations could lead to delay the diagnosis in the early stage of disease. In these cases, thymic pathology is present in more than 50% of cases. Pathological findings can be consistent of polymyositis (63%), dermatomyositis (25%) or granulomatosis (12%). Accurate clinical manifestations and severity of IM in MG, including muscle specific antibodies (MSA) and muscle MRI, have not been systematically investigated and focal or mild subclinical myositis have not been reported. We observed that focal myositis or asymptomatic CK elevation can also occur in MG. In this review we have also retrospectively re-analyzed the clinical, serological, pathological and muscle imaging data from 13 patients with MG- IM from our cohort of 441 MG patients (2,9%). Clinical onset occurred simultaneously in 10/13 patients, whereas in 2 patients the IM appeared later in MG disease course (range 10-14 years) and conversely in 1 patient MG symptoms occurred later in IM disease course (4 years). Median age at disease onset was 51 year (range 24-73 years) regardless of clinical onset (MG or IM). Median clinical follow-up was 88 months (range 31-237 months). IM was suspected by CK elevation in all patients (ranging 800-3000 UI/L at first detection) and non-fatigable muscle weakness unresponsive to acetylcholinesterase inhibitors. All the patients presented mild to moderate MG symptoms. Three main categories of muscle involvement, sometimes overlapping, were recognizable: distal, proximal and subclinical myositits, leading to three main clinical groups (A,B,C) and two overlapping subgroups (A/B and B/C). Thymus pathology was present in 10/13 patients. Anti-AChR was detected in al all patients associated with anti-Titin and -RyR1 in those patients with thymoma. No MSA, nor MAA antibodies were detected. Muscle biopsy confirmed IM in all patients. In conclusion we redefined the clinical spectrum of muscle involvement in MG-IM association, which represent a continuum among 3 main clinical groups: distal, proximal and subclinical muscle involvement. Minimal muscle involvement and focal myositis could be underestimated among myasthenic patients and early aggressive immunotherapy could be required in focal group." @default.
• W3006295669 created "2020-02-24" @default.
• W3006295669 creator A5004831826 @default.
• W3006295669 creator A5015008175 @default.
• W3006295669 creator A5023311837 @default.
• W3006295669 creator A5023759839 @default.
• W3006295669 creator A5024633714 @default.
• W3006295669 creator A5032683796 @default.
• W3006295669 creator A5035489373 @default.
• W3006295669 creator A5043153315 @default.
• W3006295669 creator A5049908982 @default.
• W3006295669 creator A5050657369 @default.
• W3006295669 creator A5051711446 @default.
• W3006295669 creator A5059706604 @default.
• W3006295669 creator A5062150075 @default.
• W3006295669 creator A5063404645 @default.
• W3006295669 creator A5070437388 @default.
• W3006295669 creator A5070581129 @default.
• W3006295669 creator A5073287634 @default.
• W3006295669 creator A5076842090 @default.
• W3006295669 date "2020-04-01" @default.
• W3006295669 modified "2023-10-12" @default.
• W3006295669 title "Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients" @default.
• W3006295669 cites W1561460904 @default.
• W3006295669 cites W1568142966 @default.
• W3006295669 cites W156992901 @default.
• W3006295669 cites W1972329861 @default.
• W3006295669 cites W2016782225 @default.
• W3006295669 cites W2050001367 @default.
• W3006295669 cites W2061825050 @default.
• W3006295669 cites W2066178717 @default.
• W3006295669 cites W2068618703 @default.
• W3006295669 cites W2094913938 @default.
• W3006295669 cites W2096623062 @default.
• W3006295669 cites W2108207836 @default.
• W3006295669 cites W2109351747 @default.
• W3006295669 cites W2138753843 @default.
• W3006295669 cites W2161320987 @default.
• W3006295669 cites W2162856159 @default.
• W3006295669 cites W2167689669 @default.
• W3006295669 cites W2470633658 @default.
• W3006295669 cites W2512040085 @default.
• W3006295669 cites W2605603145 @default.
• W3006295669 cites W2612336567 @default.
• W3006295669 cites W2731014799 @default.
• W3006295669 cites W2747440871 @default.
• W3006295669 cites W2750377819 @default.
• W3006295669 cites W2783975356 @default.
• W3006295669 cites W2792190570 @default.
• W3006295669 cites W2885188094 @default.
• W3006295669 cites W2901128794 @default.
• W3006295669 cites W2903468548 @default.
• W3006295669 cites W2906040336 @default.
• W3006295669 cites W2910499839 @default.
• W3006295669 cites W2912566650 @default.
• W3006295669 cites W2919659463 @default.
• W3006295669 cites W2960366490 @default.
• W3006295669 cites W2967919775 @default.
• W3006295669 cites W4210315732 @default.
• W3006295669 cites W4211188347 @default.
• W3006295669 cites W4246582376 @default.
• W3006295669 doi "https://doi.org/10.1016/j.autrev.2020.102498" @default.
• W3006295669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32062029" @default.
• W3006295669 hasPublicationYear "2020" @default.
• W3006295669 type Work @default.
• W3006295669 sameAs 3006295669 @default.
• W3006295669 citedByCount "30" @default.
• W3006295669 countsByYear W30062956692020 @default.
• W3006295669 countsByYear W30062956692021 @default.
• W3006295669 countsByYear W30062956692022 @default.
• W3006295669 countsByYear W30062956692023 @default.
• W3006295669 crossrefType "journal-article" @default.
• W3006295669 hasAuthorship W3006295669A5004831826 @default.
• W3006295669 hasAuthorship W3006295669A5015008175 @default.
• W3006295669 hasAuthorship W3006295669A5023311837 @default.
• W3006295669 hasAuthorship W3006295669A5023759839 @default.
• W3006295669 hasAuthorship W3006295669A5024633714 @default.
• W3006295669 hasAuthorship W3006295669A5032683796 @default.
• W3006295669 hasAuthorship W3006295669A5035489373 @default.
• W3006295669 hasAuthorship W3006295669A5043153315 @default.
• W3006295669 hasAuthorship W3006295669A5049908982 @default.
• W3006295669 hasAuthorship W3006295669A5050657369 @default.
• W3006295669 hasAuthorship W3006295669A5051711446 @default.
• W3006295669 hasAuthorship W3006295669A5059706604 @default.
• W3006295669 hasAuthorship W3006295669A5062150075 @default.
• W3006295669 hasAuthorship W3006295669A5063404645 @default.
• W3006295669 hasAuthorship W3006295669A5070437388 @default.
• W3006295669 hasAuthorship W3006295669A5070581129 @default.
• W3006295669 hasAuthorship W3006295669A5073287634 @default.
• W3006295669 hasAuthorship W3006295669A5076842090 @default.
• W3006295669 hasConcept C113280763 @default.
• W3006295669 hasConcept C126322002 @default.
• W3006295669 hasConcept C142724271 @default.
• W3006295669 hasConcept C207886595 @default.
• W3006295669 hasConcept C2777300911 @default.
• W3006295669 hasConcept C2777910003 @default.
• W3006295669 hasConcept C2778105408 @default.
• W3006295669 hasConcept C2778751314 @default.

• next